FDA’s Cardio-Renal AdComm Losing Some Of Its Anticoagulant Experience

Mori Krantz and Sanjay Kaul are rotating off the committee after participating in all three reviews of J&J/Bayer’s Factor Xa inhibitor rivaroxaban, and nearly all of the meetings on novel anti-clotting agents.